Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

) soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers said it earned $1.43 billion in the quarter, or 87 cents a share, compared with $373 million, or 23 cents a share, a year earlier. Bristol-Myers increased its full-year earnings forecast by 10 cents a share to $4.20 to $4.30 a share.Sales of Eliquis rose 24% to $2.04 billion and Orencia sales rose 9% to $778 million. Both drugs performed better than analysts expected.

The result is likely to further solidify Keytruda as an initial treatment for advanced lung cancer, by far the most lucrative oncology market.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Tesla's second-quarter earnings fall short of Wall Street expectationsThe company's stock price fell more than 8% in after-hours trading following the earnings release on Wednesday. Prince Philips issued a statement to clarify the situation thoroughly. He lay awake all night. .. We will ask for experts’ opinions on this.
مصدر: BusinessInsider - 🏆 729. / 51 اقرأ أكثر »